2. Signaling Pathways
  3. Epigenetics
  4. Histone Demethylase
  5. Histone Demethylase Isoform
  6. Histone Demethylase Inhibitor

Histone Demethylase Inhibitor

Histone Demethylase Inhibitors (83):

Cat. No. Product Name Effect Purity
  • HY-12782T
    Iadademstat dihydrochloride
    		Inhibitor 99.98%
    Iadademstat (ORY-1001) dihydrochloride is a selective irreversible lysine (K)-specific demethylase 1A (KDM1A/LSD1) inhibitor.
  • HY-100546A
    GSK-LSD1 dihydrochloride
    		Inhibitor ≥98.0%
    GSK-LSD1 dihydrochloride is a potent, selective and irreversible lysine specific demethylase 1 (LSD1) inhibitor with an IC50 of 16 nM.
  • HY-18632A
    GSK2879552 dihydrochloride
    		Inhibitor 99.19%
    GSK2879552 dihydrochloride an orally active, selective and irreversible inhibitor of lysine specific demethylase 1 (LSD1/KDM1A), with potential antineoplastic activity.
  • HY-100760
    Toxoflavin
    		Inhibitor 99.88%
    Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor and antibiotic activity.
  • HY-168433
    LSD1/EGFR-IN-1
    		Inhibitor
    LSD1/EGFR-IN-1 (compound L-1) is a potent inhibitor of LSD1, EGFRT790M/L858R and EGFRL858R/T790M/C797S, with IC50s of 6.24 and 2.06 and 5.01 μM, respectively. LSD1/EGFR-IN-1 plays an important role in cancer research.
  • HY-111048
    Corin
    		Inhibitor 98.16%
    Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a Ki(inact) of 110 nM for LSD1 and an IC50 of 147 nM for HDAC1.
  • HY-139782
    SKLB325
    		Inhibitor 99.23%
    SKLB325 is a Jumonji domain-containing 6 (JMJD6) inhibitor with a binding affinity (KD) value of 0.755 μM, and the IC50 value of 0.7797 μM. SKLB325 exhibits antitumor effects on ovarian cancer in vivo and in vitro. SKLB325 induces apoptosis. SKLB325 exhibits remarkable antitumor efficacy in renal cell carcinoma (RCC) .
  • HY-Q36392
    JNJ-9350
    		Inhibitor 99.21%
    JNJ-9350 is an inhibitor of spermine oxidase (SMOX) with an IC50 value of 0.01 μM. JNJ-9350 also inhibits polyamine oxidase (PAO) with an IC50 value of 0.79 μM. JNJ-9350 can be used for the research of cancer.
  • HY-12315
    N-Oxalylglycine
    		Inhibitor 99.28%
    N-Oxalylglycine (N-Oxaloglycine) is a Jumonji C-domain-containing histone lysine demethylase inhibitor. N-Oxalylglycine inhibits JMJD2A, JMJD2C and JMJD2D. N-Oxalylglycine also inhibits HIF prolylhydroxylase domain-1 (PHD-1) and PHD-2, with an IC50 of 2.1 μM and 5.6 μM, respectively.
  • HY-112623
    Vafidemstat
    		Inhibitor 99.53%
    Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor.
  • HY-162275
    JMJD1C-IN-1
    		Inhibitor 99.99%
    JMJD1C-IN-1 (compound 193D7) is an inhibitor of JMJD1C with oral activity. JMJD1C-IN-1 targets tumor Treg cells without affecting systemic immune homeostasis.
  • HY-15221
    Methylstat
    		Inhibitor 98.85%
    Methylstat is a potent histone demethylases inhibitor. Methylstat shows anti-proliferative activity with low cytotoxicity. Methylstat induces apoptosis and cell cycle arrest at G0/G1 phase. Methylstat increases the expression of p53 and p21 protein levels. Methylstat inhibits angiogenesis induced by various cytokines. Methylstat can be used as a chemical probe for addressing its role in angiogenesis.
  • HY-W017132
    2,4-PDCA
    		Inhibitor 99.80%
    2,4-PDCA (2,4 pyridine dicarboxylic acid) is a broad-spectrum inhibitor of 2OG oxygenase, including JmjC domain-containing family of histone demethylases (JHDMs). 2,4-PDCA is a target chemical in the field of bio-based plastics.
  • HY-139434
    JMJD6-IN-1
    		Inhibitor 99.69%
    JMJD6-IN-1 (Compound 1-3) is a JMJD6 inhibitor, with an inhibition rate of 82% at 10 μM. JMJD6-IN-1 inhibits MCF-7 and HCC4006 cell proliferation with IC50s of 19.2 μM and 25.2 μM. JMJD6-IN-1 can be used for research of cancers.
  • HY-110130
    RN-1 dihydrochloride
    		Inhibitor 99.13%
    RN-1 dihydrochloride is a potent, brain-penetrant, irreversible and selective lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 70 nM. RN-1 dihydrochloride exhibits selectivity for LSD1 over MAO-A and MAO-B with IC50 values of 0.51 μM and 2.785 μM respectively.
  • HY-19333
    OG-L002
    		Inhibitor 99.81%
    OG-L002 is a potent and highly selective LSD1 inhibitor with an IC50 of 0.02 μM. OG-L002 is a potent monoamine oxidases (MAO) inhibitor with IC50s of 1.38 μM and 0.72 μM for MAO-A and MAO-B, respectively. OG-L002 potently inhibits the expression of HSV IE genes.
  • HY-119397A
    KDM5-C49 hydrochloride
    		Inhibitor 99.95%
    KDM5-C49 (KDOAM-20) hydrochloride is a potent and selective inhibitor of KDM5 demethylases, with IC50s of 40 nM, 160 nM, and 100 nM for KDM5A, KDM5B, and KDM5C enzymes, respectively. KDM5-C49 hydrochloride can be used for the research of cancer.
  • HY-114519
    Helenalin acetate
    		Inhibitor 98.59%
    Helenalin acetate, a natural NF-κB inhibitor, is a potent C/EBPβ inhibitor. Helenalin acetate has anti-inflammatory and anticancer activities.
  • HY-103713A
    Seclidemstat mesylate
    		Inhibitor 99.60%
    Seclidemstat (SP-2577) mesylate is a potent noncompetitive and reversible KDM1A (LSD1) inhibitor (Ki=31 nM, IC50=13 nM). Seclidemstat mesylate promotes antitumor immunity in switch/sucrose nonfermentable (SWI/SNF) complex mutated ovarian cancer, as well as inhibit virus production, viral DNA replication, and late gene expression. Seclidemstat mesylate can be used for the research of Ewing Sarcoma.
  • HY-132896
    KDM4-IN-3
    		Inhibitor 99.36%
    KDM4-IN-3 is a KDM4 inhibitor that exhibits improved potency in biochemical assays, is cell-permeable, and kills prostate cancer cells at low micromolar concentrations.